Introduction:

the COVID-19 pandemic has come to undermine human physical and spiritual health. Many evidences point to the role of neutrophil extracellular traps and their combat weapon: Myeloperoxidase enzyme, as part of the immune response against this lethal infection.

Objective:

to determine the reference values of the enzyme myeloperoxidase, biomarker for the evaluation of clinical deterioration in patients with Covid-19.

Methods:

in the Department of Biomedical Research of the Direction of Science and Technological Innovation, University of Medical Sciences of Villa Clara, the determination of the enzyme Myeloperoxidase was implemented, its analytical validation and the estimation of reference values in a supposedly healthy population were carried out. For this purpose, a quantitative, transversal and descriptive research protocol was carried out involving patients from the Provincial Blood Bank. Blood plasma was used as a biological sample and myeloperoxidase activity was estimated. Interfractal limits were determined between 2.5 and 97.5 percentiles.

Results:

the analytical parameters of linearity, precision and trueness of the method corresponded to the requirements of international standards. The reference values for the healthy population studied were in the range between 110-960 U/L.

Conclusions:

the reference values are related to other reports and contribute to the evaluation of patient status and as a prognostic biomarker of severity of the patient affected by COVID-19.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )